Skip to main content
Top
Published in: Clinical & Experimental Metastasis 3/2016

01-03-2016 | Research Paper

The predictive capacity of apparent diffusion coefficient (ADC) in response assessment of brain metastases following radiation

Authors: Raphael Jakubovic, Stephanie Zhou, Chris Heyn, Hany Soliman, Liyang Zhang, Richard Aviv, Arjun Sahgal

Published in: Clinical & Experimental Metastasis | Issue 3/2016

Login to get access

Abstract

To investigate the predictive capacity of the apparent diffusion coefficient (ADC) as a biomarker of radiation response in brain metastases. Seventy brain metastases from 42 patients treated with either stereotactic radiosurgery or whole brain radiotherapy were imaged at baseline, 1 week, and 1 month post-treatment using diffusion-weighted MRI. Mean and median relative ADC for metastases was calculated by normalizing ADC measurements to baseline ADC. At 1 year post-treatment, or last available follow-up MRI, volume criteria determined final tumour response status. Uni- and multivariate analysis was used to account for factors associated with tumour response at 1 week and 1 month. A generalized estimating equations model took into consideration multiple tumours per subject. Optimal thresholds that distinguished responders from non-responders, as well as sensitivity and specificity were determined by receiver operator characteristic analysis and Youden’s index. Lower relative ADC values distinguished responders from non-responders at 1 week and 1 month (P < 0.05). Optimal cut-off values for response were 1.060 at 1 week with a sensitivity and specificity of 75.0 and 56.3 %, respectively. At 1 month, the cut-off was 0.971 with a sensitivity and specificity of 70.0 and 68.8 %, respectively. A multivariate general estimating equations analysis identified no prior radiation [odds ratio (OR) 0.211 and 0.137, P = 0.033 and 0.0177], and a lower median relative ADC at 1 week and 1 month (OR 0.619 and 0.694, P = 0.0036 and 0.005), as predictors of tumour response. Lower relative ADC values at 1 week and 1 month following radiation distinguished responders from non-responders and may be a promising biomarker of early radiation response.
Literature
1.
go back to reference Schüttrumpf LH, Niyazi M, Nachbichler SB, Manapov F, Jansen N, Siefert A et al (2014) Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1–3 cerebral metastases. Radiat Oncol 9:105. doi:10.1186/1748-717X-9-105 CrossRefPubMedPubMedCentral Schüttrumpf LH, Niyazi M, Nachbichler SB, Manapov F, Jansen N, Siefert A et al (2014) Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1–3 cerebral metastases. Radiat Oncol 9:105. doi:10.​1186/​1748-717X-9-105 CrossRefPubMedPubMedCentral
3.
go back to reference Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. J Am Med Assoc 295:2483–2491. doi:10.1001/jama.295.21.2483 CrossRef Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. J Am Med Assoc 295:2483–2491. doi:10.​1001/​jama.​295.​21.​2483 CrossRef
4.
go back to reference Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. doi:10.1016/S1470-2045(09)70263-3 CrossRefPubMed Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. doi:10.​1016/​S1470-2045(09)70263-3 CrossRefPubMed
5.
go back to reference Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141. doi:10.1200/JCO.2010.30.1655 CrossRefPubMedPubMedCentral Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141. doi:10.​1200/​JCO.​2010.​30.​1655 CrossRefPubMedPubMedCentral
6.
go back to reference Tsao M, Xu W, Sahgal A (2012) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118:2486–2493. doi:10.1002/cncr.26515 CrossRefPubMed Tsao M, Xu W, Sahgal A (2012) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118:2486–2493. doi:10.​1002/​cncr.​26515 CrossRefPubMed
7.
go back to reference Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M et al (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91:710–717. doi:10.1016/j.ijrobp.2014.10.024 CrossRefPubMed Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M et al (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91:710–717. doi:10.​1016/​j.​ijrobp.​2014.​10.​024 CrossRefPubMed
8.
go back to reference Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672. doi:10.1016/S0140-6736(04)16250-8 CrossRefPubMed Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672. doi:10.​1016/​S0140-6736(04)16250-8 CrossRefPubMed
9.
go back to reference Chang EL, Shiu AS, Lii M-F, Rhines LD, Mendel E, Mahajan A et al (2004) Phase I clinical evaluation of near-simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases. Int J Radiat Oncol Biol Phys 59:1288–1294. doi:10.1016/j.ijrobp.2004.04.025 CrossRefPubMed Chang EL, Shiu AS, Lii M-F, Rhines LD, Mendel E, Mahajan A et al (2004) Phase I clinical evaluation of near-simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases. Int J Radiat Oncol Biol Phys 59:1288–1294. doi:10.​1016/​j.​ijrobp.​2004.​04.​025 CrossRefPubMed
10.
go back to reference Sahgal A (2015) Point/counterpoint: Stereotactic radiosurgery without whole-brain radiotherapy for patients with a limited number of brain metastases: the current standard of care? Neuro-Oncology. 17(7):916–918CrossRefPubMed Sahgal A (2015) Point/counterpoint: Stereotactic radiosurgery without whole-brain radiotherapy for patients with a limited number of brain metastases: the current standard of care? Neuro-Oncology. 17(7):916–918CrossRefPubMed
12.
13.
go back to reference Nagane M, Kobayashi K, Tanaka M, Tsuchiya K, Shishido-Hara Y, Shimizu S et al (2014) Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. Int J Clin Oncol 19:16–23. doi:10.1007/s10147-013-0517-x CrossRefPubMed Nagane M, Kobayashi K, Tanaka M, Tsuchiya K, Shishido-Hara Y, Shimizu S et al (2014) Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. Int J Clin Oncol 19:16–23. doi:10.​1007/​s10147-013-0517-x CrossRefPubMed
14.
go back to reference Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR et al (2011) Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 32:882–889. doi:10.3174/ajnr.A2385 CrossRefPubMed Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR et al (2011) Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 32:882–889. doi:10.​3174/​ajnr.​A2385 CrossRefPubMed
15.
go back to reference Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291–298CrossRefPubMed Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291–298CrossRefPubMed
16.
go back to reference Ostergaard L, Hochberg FH, Rabinov JD, Sorensen AG, Lev M, Kim L et al (1999) Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 90:300–305. doi:10.3171/jns.1999.90.2.0300 CrossRefPubMed Ostergaard L, Hochberg FH, Rabinov JD, Sorensen AG, Lev M, Kim L et al (1999) Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 90:300–305. doi:10.​3171/​jns.​1999.​90.​2.​0300 CrossRefPubMed
17.
go back to reference Follwell MJ, Khu KJ, Cheng L, Xu W, Mikulis DJ, Millar B-A et al (2012) Volume specific response criteria for brain metastases following salvage stereotactic radiosurgery and associated predictors of response. Acta Oncol 51:629–635. doi:10.3109/0284186X.2012.681066 CrossRefPubMed Follwell MJ, Khu KJ, Cheng L, Xu W, Mikulis DJ, Millar B-A et al (2012) Volume specific response criteria for brain metastases following salvage stereotactic radiosurgery and associated predictors of response. Acta Oncol 51:629–635. doi:10.​3109/​0284186X.​2012.​681066 CrossRefPubMed
18.
go back to reference Tomura N, Narita K, Izumi J, Suzuki A, Anbai A, Otani T et al (2006) Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 30:496–500CrossRefPubMed Tomura N, Narita K, Izumi J, Suzuki A, Anbai A, Otani T et al (2006) Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 30:496–500CrossRefPubMed
19.
go back to reference Lee C-C, Wintermark M, Xu Z, Yen C-P, Schlesinger D, Sheehan JP (2014) Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery. J Neurooncol 118:351–361. doi:10.1007/s11060-014-1439-9 CrossRefPubMed Lee C-C, Wintermark M, Xu Z, Yen C-P, Schlesinger D, Sheehan JP (2014) Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery. J Neurooncol 118:351–361. doi:10.​1007/​s11060-014-1439-9 CrossRefPubMed
20.
go back to reference Hein PA, Kremser C, Judmaier W, Griebel J, Pfeiffer K-P, Kreczy A et al (2003) Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 45:214–222CrossRefPubMed Hein PA, Kremser C, Judmaier W, Griebel J, Pfeiffer K-P, Kreczy A et al (2003) Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 45:214–222CrossRefPubMed
22.
go back to reference Mintorovitch J, Yang GY, Shimizu H, Kucharczyk J, Chan PH, Weinstein PR (1994) Diffusion-weighted magnetic resonance imaging of acute focal cerebral ischemia: comparison of signal intensity with changes in brain water and Na+, K(+)-ATPase activity. J Cereb Blood Flow Metab 14:332–336. doi:10.1038/jcbfm.1994.40 CrossRefPubMed Mintorovitch J, Yang GY, Shimizu H, Kucharczyk J, Chan PH, Weinstein PR (1994) Diffusion-weighted magnetic resonance imaging of acute focal cerebral ischemia: comparison of signal intensity with changes in brain water and Na+, K(+)-ATPase activity. J Cereb Blood Flow Metab 14:332–336. doi:10.​1038/​jcbfm.​1994.​40 CrossRefPubMed
24.
go back to reference Farjam R, Tsien CI, Feng FY, Gomez-Hassan D, Hayman JA, Lawrence TS et al (2014) Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy. Neuro Oncol 16:131–139. doi:10.1093/neuonc/not153 CrossRefPubMedPubMedCentral Farjam R, Tsien CI, Feng FY, Gomez-Hassan D, Hayman JA, Lawrence TS et al (2014) Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy. Neuro Oncol 16:131–139. doi:10.​1093/​neuonc/​not153 CrossRefPubMedPubMedCentral
25.
go back to reference Asao C, Korogi Y, Kitajima M, Hirai T, Baba Y, Makino K et al (2005) Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. Am J Neuroradiol 26:1455–1460PubMed Asao C, Korogi Y, Kitajima M, Hirai T, Baba Y, Makino K et al (2005) Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. Am J Neuroradiol 26:1455–1460PubMed
26.
go back to reference Jakubovic R, Sahgal A, Soliman H, Milwid R, Zhang L, Eilaghi A et al (2014) Magnetic resonance imaging-based tumour perfusion parameters are biomarkers predicting response after radiation to brain metastases. Clin Oncol 26:704–712. doi:10.1016/j.clon.2014.06.010 CrossRef Jakubovic R, Sahgal A, Soliman H, Milwid R, Zhang L, Eilaghi A et al (2014) Magnetic resonance imaging-based tumour perfusion parameters are biomarkers predicting response after radiation to brain metastases. Clin Oncol 26:704–712. doi:10.​1016/​j.​clon.​2014.​06.​010 CrossRef
32.
go back to reference Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. Am J Neuroradiol 25:201–209PubMed Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. Am J Neuroradiol 25:201–209PubMed
33.
go back to reference Mahmood F, Johannesen HH, Geertsen P, Opheim GF, Hansen RH (2015) The effect of region of interest strategies on apparent diffusion coefficient assessment in patients treated with palliative radiation therapy to brain metastases. Acta Oncol 54:1529–1534. doi:10.3109/0284186X.2015.1061211 CrossRefPubMed Mahmood F, Johannesen HH, Geertsen P, Opheim GF, Hansen RH (2015) The effect of region of interest strategies on apparent diffusion coefficient assessment in patients treated with palliative radiation therapy to brain metastases. Acta Oncol 54:1529–1534. doi:10.​3109/​0284186X.​2015.​1061211 CrossRefPubMed
34.
go back to reference Hiwatashi A, Kinoshita T, Moritani T, Wang HZ, Shrier DA, Numaguchi Y et al (2003) Hypointensity on diffusion-weighted MRI of the brain related to T2 shortening and susceptibility effects. Am J Roentgenol 181:1705–1709. doi:10.2214/ajr.181.6.1811705 CrossRef Hiwatashi A, Kinoshita T, Moritani T, Wang HZ, Shrier DA, Numaguchi Y et al (2003) Hypointensity on diffusion-weighted MRI of the brain related to T2 shortening and susceptibility effects. Am J Roentgenol 181:1705–1709. doi:10.​2214/​ajr.​181.​6.​1811705 CrossRef
Metadata
Title
The predictive capacity of apparent diffusion coefficient (ADC) in response assessment of brain metastases following radiation
Authors
Raphael Jakubovic
Stephanie Zhou
Chris Heyn
Hany Soliman
Liyang Zhang
Richard Aviv
Arjun Sahgal
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 3/2016
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9778-x

Other articles of this Issue 3/2016

Clinical & Experimental Metastasis 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine